

RESEARCH ARTICLE

Cite this: *RSC Med. Chem.*, 2021, 12, 1374

Design, synthesis and biological evaluation of combretastatin A-4 sulfamate derivatives as potential anti-cancer agents†

Leilei Huang,^a Jinwen Huang,^a *^{abc} Hui Nie,^a Yingzi Li,^a Lixing Song^a and Fanhong Wu^{*ab}

A series of combretastatin A-4 (CA-4) sulfamate derivatives were synthesized and their structure–activity relationship on tubulin, arylsulfatase and tumor cell antiproliferation inhibition was studied. Among them, compound **16a** showed excellent potency as well as CA-4 under the same conditions against six tumor cells including HTC-116, HeLa, HepG2, MGC803, MKN45 and MCF-7 cells, respectively. Molecular docking revealed that several important hydrogen bond interactions were formed between the sulfamate group of **16a** and the colchicine binding site of tubulin and steroid sulfatase respectively. Although compound **16a** was less active than CA-4 in regard to its *in vitro* activity as an inhibitor of tubulin polymerization, it was effective as an inhibitor of arylsulfatase. This novel combretastatin A-4 sulfamate derivative has the potential to be developed as a dual inhibitor of tubulin polymerization and arylsulfatase for cancer therapy.

Received 2nd November 2020,
Accepted 17th May 2021

DOI: 10.1039/d0md00372g

rsc.li/medchem

The occurrence and development of cancer is a complex and long process, and cancer is one of the major causes for the increase in world mortality.^{1–3} In particular, breast cancer is the most common cancer with high incidence rates in women, making up about one third of global cancer diagnoses for women, and it is one of the major health problems in the world.^{4–7} In the past few decades, great progress was made in molecular-targeted anti-tumor drug research.⁸ Tubulin and arylsulfatase are promising targets in cancer therapy. Tubulin is the fundamental unit of microtubules in the cell, and it plays a critical role in maintaining the shape, movement and intracellular material transportation in the cell. Tubulin targeted inhibitors are effective in the treatment of cancer.⁹ There are three major binding pockets in tubulin, which were named after three different drugs, paclitaxel, vincristine and colchicine, respectively. Tubulin inhibitors binding to these pockets can arrest tumor cell mitosis and induce apoptosis.^{9,10} Paclitaxel and vincristine are effective chemotherapy drugs widely used in the clinic, and some marketed drugs were developed targeting the paclitaxel and vincristine binding sites.¹⁰ However, colchicine was not used in treating cancer

due to its high toxicity, and studies on inhibitors targeting colchicine binding sites are one of the hotspots in antineoplastic drug research.¹¹


Arylsulfatases are one kind of a protein family in charge of the hydrolysis of sulfonates, and they play a significant role in the hormonal regulation in cells, the degradation of cell components and signaling pathway regulation.¹² The abnormal activity of arylsulfatases in the body is closely related to the growth of tumors. Currently, there are four extensively studied arylsulfatases, namely lysosomal arylsulfatases (ARS-A and ARS-B), endoplasmic reticulum arylsulfatase (ARS-C) and extracellular arylsulfatase (Hsulf-1). In the clinic, the activity of ARS-A and ARS-B has become an important indicator in tumor diagnosis as the ARS activity in urine would significantly increase in all types of tumor patients.¹³ ARS-C, also known as steroid sulfatase (STS), is majorly responsible for adjusting the balance of hormone levels (Scheme 1) by hydrolysis of estrone sulfate (E1S) and dehydroepiandrosterone sulfate (DHEAS) in order to release

^a Department of Pharmaceutical Engineering, School of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai, China. E-mail: goldven@sit.edu.cn, wfh@sit.edu.cn

^b Shanghai Engineering Research Center of Green Fluoropharmaceutical Technology, China

^c Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, CAS, China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0md00372g



Scheme 1 The role of steroid sulfatase in hormone regulation.

estrone and dehydroepiandrosterone (DHEA). The abnormal state of STS will imbalance the hormone levels in the body as well as promote the growth and proliferation of cancer cells. Steroid sulfatase (STS) inhibitors are an effective therapy for the treatment of hormone dependent cancer such as breast and cervical cancer by inhibiting the hydrolysis of E1S.¹⁴ In the past few years, a lot of steroid sulfatase inhibitors (1–5, Fig. 1), including stilbene compounds, have been developed and they exhibit good inhibitory activity against breast cancer cells *via* inhibiting steroid sulfatase.¹⁵ The sulfamate group is an essential pharmacophore for potency, and estrone-3-*O*-sulfamate (EMATE, 1), the sulfamate derivative of estrone, is a typical representative of this kind of inhibitor.¹⁶

Combretastatin A-4 (CA-4, 6a) and combretastatin A-1 (CA-1, 7) are *cis*-stilbene type natural products originally isolated from the South African bushwillow tree *Combretum caffrum*. They inhibit tubulin polymerization by interacting with the colchicine-binding sites of tubulin, thus arresting the mitosis of tumor cells and inducing their apoptosis. In addition, CA-4 disrupts tumor vasculatures at a nontoxic dose resulting in tumor cells starving to death without affecting the healthy cell's blood supply.¹⁷ Efforts directed toward the discovery of more potent and selective vascular disrupting agents continue on a global basis.¹⁸ In recent years, a large number of structure modifications were made to find more potent CA-4 analogues,^{19,20} and among them, AVE-8062A (10) and CA-4P (11) have entered phase II/III clinical trials (Fig. 1).²⁰ Structure–activity relationship studies indicate that the *cis*-conformation is crucial for potency. Our groups also have made a lot of progress in finding more potent CA-4 analogues with improved properties by using the twin drug, prodrug and fluorine modification strategies.²¹

In addition to the strong arylsulfatase inhibition, the anti-tumor mechanism of EMATE is also related to its weak tubulin inhibition activity ($IC_{50} = 25.90 \mu\text{M}$, Table 2). 2-Methoxyestradiol (2-ME), an endogenous metabolite of 17-estradiol, is also a weak tubulin inhibitor ($IC_{50} \approx 40 \mu\text{M}$) and it can inhibit microtubule assembly and induce G2/M arrest and apoptosis in many actively dividing cell types while sparing quiescent cells.²² 2-ME can also bind to the colchicine site of tubulin. Therefore, it has potent antineoplastic activity as an apoptosis inducer and an angiogenesis inhibitor. However, 2-ME is ineffective for arylsulfatase inhibition as compared to EMATE.²² The




Fig. 1 Chemical structures of 1–12.






Fig. 2 The design of sulfamate derivatives of CA-4.

sulfamide group is a widely used pharmacophore in medicinal chemistry as it possess both hydrogen bond donors and acceptors. There are many reports about sulfamate modification of other molecular structures as a potent dual inhibitor of carbonic anhydrase and steroid sulfatase.²³ Inspired by the structure and the difference of activity in tubulin and sulfatase inhibition between EMATE and 2-ME, we speculated that sulfamate modification of CA-4 would lead to the foundation of effective dual inhibitors of both tubulin and steroid sulfatase. We hope to obtain a drug candidate with better potency, stability and pharmacokinetic profiles than CA-4 through the sulfamate derivatives of CA-4 and further structure–activity relationship (SAR) studies (Fig. 2). Herein, we reported the synthesis and biological evaluation of novel combretastatin analogues, while also discussing the molecular docking study and the SAR analysis.

Firstly, compound 16a, the sulfamate modified CA-4 (6a), was synthesized and its antiproliferation activity was



Scheme 2 Synthetic route of combretastatin A-4 sulfamate derivatives. Reagents and conditions: a) Ph₃CCl(TrCl), THF, Et₃N, rt, 2 h; b) *n*-BuLi, THF, −78 °C, 30 min, then adding 14/THF solution, −78 °C–RT, overnight; c) 37% HCl (aq.), toluene, rt, 2 h; d) NaH, DMF, RSO₂-Cl (R = NH₂, NHMe, N(Me)₂), 0 °C to RT, overnight; e) H₂ (1 atm), 10% Pd/C, EtOH, rt, 3 h.



Scheme 3 Synthetic route of combretastatin sulfamide derivatives. Reagents and conditions: a) *n*-BuLi, THF, $-78\text{ }^{\circ}\text{C}$, 30 min, then adding **13e**/THF solution, $-78\text{ }^{\circ}\text{C}$ -rt, overnight; b) Zn, CH_3COOH , 2 h, rt; c) NaH, DMF, $\text{NH}_2\text{SO}_2\text{Cl}$, $0\text{ }^{\circ}\text{C}$ -rt, overnight; d) H_2 (1 atm), 10% Pd/C, EtOH, rt, 3 h.

compared with that of CA-4 as the positive control. To our delight, compound **16a** showed excellent anti-tumor activity with respect to CA-4 under the same conditions. Next, we designed a number of combretastatin A-4 sulfamate and sulfamide derivatives to explore their structure-activity relationship. The synthetic procedures are outlined in Schemes 2 and 3. The aldehyde intermediate (**13**) was purchased or prepared following a reported protocol.^{21b} The hydroxyl group of **13** was protected with trityl to give **14**. A (*Z/E*)-stilbene mixture was obtained from the aldehyde intermediates (**14** or **13e**, in Schemes 2 and 3) and triphenyl(3,4,5-trimethoxybenzyl)phosphonium bromide (**15**) *via* the Wittig reaction, followed by deprotection of the trityl group or reduction of the nitro group to give 3-hydroxyl or 3-amino substituted (on the B ring) stilbenes (**6** and **9**,

Schemes 2 and 3). Their *Z* and *E* isomers were separated by flash column chromatography. Compounds **6** and **9** were further reacted with sulfamoyl chloride respectively to achieve the corresponding sulfamate (**16**) and sulfamide (**19**) derivatives of stilbene. The diphenylethane sulfamate and sulfamide derivatives (**17** and **20**) were obtained from the Pd/C catalyzed hydrogenation of **16** and **19**.

The *in vitro* antiproliferative activity of these compounds were evaluated *via* the CCK-8 assay by using CA-4 and EMATE as the positive control. Six human tumor cell lines, including the HTC-116, HeLa, HepG2, MGC803, MKN45 and MCF-7, were tested. The results are summarized in Table 1. Among all the analogues, only compound **16i**, the monomethylated **16a**, showed comparable potency ($\text{IC}_{50} = 3.4\text{--}11.3\text{ nM}$) to **16a** ($\text{IC}_{50} = 3.6\text{--}9.5\text{ nM}$) and CA-4 ($\text{IC}_{50} = 2.9\text{--}8.1\text{ nM}$) on the six tumor cell lines, except that its inhibitory activity ($\text{IC}_{50} = 0.53\text{ }\mu\text{M}$) on MCF-7 cells is slightly less potent than that of **16a** ($\text{IC}_{50} = 0.11\text{ }\mu\text{M}$) and CA-4 ($\text{IC}_{50} = 0.14\text{ }\mu\text{M}$). As for compound **16j**, the dimethyl substituted **16a**, its potency was reduced although it showed stronger potency on HTC-116 cells ($\text{IC}_{50} = 0.37\text{ }\mu\text{M}$) than on the other five tumor cell lines ($\text{IC}_{50} = 7.14\text{--}14.26\text{ }\mu\text{M}$). The replacement of sulfamate with sulfamide (**19a**) also led to a potency decrease compared with **16a**. **19a** showed better potency ($\text{IC}_{50} = 0.27, 0.75, 0.50\text{ }\mu\text{M}$) on HeLa, HepG2, and MGC803 than on the other three cell lines (HTC-116, MKN45 and MCF-7, $\text{IC}_{50} = 3.29, 9.56, 11.19\text{ }\mu\text{M}$). The electronic and steric effects of R-substitution also has a great influence on potency. When the methoxyl group of **16a** was replaced with a hydrogen (**16g**, R = H), difluoromethoxy (**16c**,

Table 1 The *in vitro* antiproliferation activities of combretastatin A-4 sulfamate and sulfamide derivatives against on six human tumor cells^a

Compounds		IC_{50} (mean \pm SD, μM) ^a							
Entry	R	R ¹ (R ²)N	X	HTC-116	HeLa	HepG2	MGC803	MKN45	MCF-7
CA-4	—	—	—	0.0047 \pm 0.0008	0.0029 \pm 0.0001	0.0029 \pm 0.0007	0.0060 \pm 0.0006	0.0081 \pm 0.0004	0.14 \pm 0.02
EMATE	—	—	—	0.90 \pm 0.04	0.63 \pm 0.06	0.85 \pm 0.05	0.48 \pm 0.09	0.54 \pm 0.12	0.07 \pm 0.10
16a (<i>Z</i>)	OMe	NH ₂	O	0.0050 \pm 0.0005	0.0061 \pm 0.0003	0.0036 \pm 0.0002	0.0047 \pm 0.0006	0.0095 \pm 0.0004	0.11 \pm 0.04
16b (<i>E</i>)	OMe	NH ₂	O	1.57 \pm 0.07	4.50 \pm 0.07	0.87 \pm 0.09	2.98 \pm 0.07	10.52 \pm 0.04	5.44 \pm 0.05
16c (<i>Z</i>)	OCF ₂ H	NH ₂	O	9.11 \pm 0.04	7.82 \pm 0.05	4.81 \pm 0.06	9.00 \pm 0.05	12.52 \pm 0.04	0.29 \pm 0.05
16d (<i>E</i>)	OCF ₂ H	NH ₂	O	12.84 \pm 0.03	8.42 \pm 0.04	5.54 \pm 0.05	9.24 \pm 0.04	13.84 \pm 0.04	13.79 \pm 0.03
16e (<i>Z</i>)	OEt	NH ₂	O	0.55 \pm 0.07	0.48 \pm 0.08	0.41 \pm 0.05	0.27 \pm 0.07	0.32 \pm 0.07	0.30 \pm 0.06
16f (<i>E</i>)	OEt	NH ₂	O	9.12 \pm 0.04	5.64 \pm 0.05	2.63 \pm 0.07	7.63 \pm 0.05	8.05 \pm 0.05	13.71 \pm 0.03
16g (<i>Z</i>)	H	NH ₂	O	9.50 \pm 0.03	16.30 \pm 0.03	9.36 \pm 0.05	8.53 \pm 0.04	15.32 \pm 0.02	11.10 \pm 0.04
16h (<i>E</i>)	H	NH ₂	O	40.30 \pm 0.04	19.00 \pm 0.03	11.85 \pm 0.03	27.03 \pm 0.02	25.04 \pm 0.02	27.44 \pm 0.02
16i (<i>Z</i>)	OMe	NHMe	O	0.0113 \pm 0.0003	0.0034 \pm 0.0005	0.0039 \pm 0.0010	0.0037 \pm 0.0006	0.0073 \pm 0.0003	0.53 \pm 0.03
16j (<i>Z</i>)	OMe	N(Me) ₂	O	0.37 \pm 0.07	14.26 \pm 0.04	9.96 \pm 0.03	7.14 \pm 0.03	8.95 \pm 0.37	11.06 \pm 0.04
19a (<i>Z</i>)	OMe	NH ₂	NH	3.29 \pm 0.77	0.27 \pm 0.06	0.75 \pm 0.06	0.50 \pm 0.07	9.56 \pm 0.09	11.19 \pm 0.06
19b (<i>E</i>)	OMe	NH ₂	NH	8.65 \pm 0.04	0.38 \pm 0.05	7.53 \pm 0.06	6.19 \pm 0.06	18.87 \pm 0.03	17.09 \pm 0.04
17a ^b	OMe	NH ₂	O	2.63 \pm 0.08	9.04 \pm 0.04	1.06 \pm 0.05	3.61 \pm 0.08	11.87 \pm 0.04	5.91 \pm 0.06
17a ^b	OCF ₂ H	NH ₂	O	26.48 \pm 0.02	35.65 \pm 0.01	15.88 \pm 0.02	23.26 \pm 0.02	71.38 \pm 0.02	52.74 \pm 0.03
17c ^b	OEt	NH ₂	O	10.16 \pm 0.03	2.930 \pm 0.07	3.65 \pm 0.07	3.59 \pm 0.06	7.67 \pm 0.06	14.75 \pm 0.02
17d ^b	H	NH ₂	O	52.49 \pm 0.02	27.06 \pm 0.03	12.03 \pm 0.03	17.64 \pm 0.04	25.70 \pm 0.03	>100
20 ^b	OMe	NH ₂	NH	30.63 \pm 0.04	2.926 \pm 0.07	8.10 \pm 0.05	8.21 \pm 0.04	73.88 \pm 0.05	20.13 \pm 0.03

^a The experiment was carried out using an EnoGeneCell™ counting Kit-8 (CCK-8) assay. ^b Saturated bond linked compound.

Table 2 The *in vitro* inhibitory activities of combretastatin A-4 sulfamate derivatives against arylsulfatase and tubulin

Entry	R ¹	R ² (R ³)N	X	IC ₅₀ ± SD (μM)	
				Arylsulfatase ^b	Tubulin ^c
16a (Z)	OMe	NH ₂	O	6.16 ± 0.55	6.60 ± 0.80
16b (E)	OMe	NH ₂	O	12.86 ± 0.25	55.70 ± 6.00
16c (Z)	OCF ₂ H	NH ₂	O	4.64 ± 1.42	72.60 ± 10.7
16e (Z)	OEt	NH ₂	O	90.19 ± 7.83	3.10 ± 1.10
16g (Z)	H	NH ₂	O	0.47 ± 0.01	>100
16i (Z)	OMe	NHMe	O	>100	1.80 ± 0.00
16j (Z)	OMe	N(Me) ₂	O	>100	12.50 ± 1.50
17a^a	OMe	NH ₂	O	>100	>100
19a (Z)	OMe	NH ₂	NH	>100	86.20 ± 6.40
EMATE	—	—	—	5.01 ± 0.01	25.90 ± 7.10
CA-4	—	—	—	>100	1.00 ± 0.20


^a Saturated bond linked compound. ^b Steroid sulfatase. ^c Tubulin polymerization.

R = OCF₂H) or ethoxy (**16e**, R = OEt) group, their cellular potency decreased compared with that of **16a** and **CA-4**. In addition, it was observed that the *cis*-double bond linked compounds (**16a**, **16c**, **16e**, **16g** and **19a**) showed better cellular potency than the *trans*-double bond (**16b**, **16d**, **16f**, **16h** and **19e**) and saturated bond linked compounds (**17a–17d**, **20**). A CA-4 sulfate derivative (CA4S, Fig. 2) was identified as a phase II metabolite of CA4.²⁴ We have also synthesized it as a control; however, it is ineffective in tumor cell cytotoxicity assays (IC₅₀ > 100 μM).

In order to verify the effectivity of these novel sulfamate derivatives of CA-4 on both arylsulfatase and tubulin, we tested their inhibitory activity on steroid sulfatase and tubulin polymerization with EMATE and CA-4 as the control, and the results are summarized in Table 2. The half inhibition rate (IC₅₀) of EMATE on steroid sulfatase and tubulin polymerization is 5.01 μM and 25.90 μM, respectively. The test inhibitory potency of combretastatin A-4 on tubulin (IC₅₀ = 1.0 μM) is consistent with literature reports; however, it is ineffective on steroid sulfatase. When the hydroxyl of CA-4 was modified by sulfamide (**16a**), it showed a slightly lower potency (IC₅₀ = 6.60 μM) on tubulin polymerization inhibition than CA-4 together with a

comparable potency (IC₅₀ = 6.16 μM) on steroid sulfatase to that of EMATE. By comparing the anti-proliferation activities and the relationship of the steroid sulfatase and tubulin inhibition potencies of CA-4 and **16a**, we can conclude that **16a** is a dual inhibitor, with the additional steroid sulfatase inhibition compensating for the lost contribution of tubulin polymerization inhibition to its anti-tumor activity. From the SAR analysis (described in the ESI†) based on arylsulfatase and tubulin polymerization inhibition (Table 2), we can conclude the following: 1) the *cis*-isomers show better activity for arylsulfatase and tubulin polymerization inhibition than the *trans*-isomers and saturated bond linked analogues. 2) The electronic and steric effects of R-groups are different on the two targets. Electron withdrawing groups are favorable for arylsulfatase inhibition but are unfavorable for tubulin inhibition at the same time. Meanwhile, bulky groups are favorable for tubulin inhibition but unfavorable for arylsulfatase inhibition. 3) The amino group of **16a** probably has a critical hydrogen bond interaction with the binding site of both targets. By comparing with **16a**, monomethyl substitution increased the potency while dimethyl substitution decreased the potency for tubulin polymerization inhibition. However, the substitution of the amino group of **16a** will lead to the loss of potency on arylsulfatase. 4) Replacing the sulfamate group with sulfamide decreases the potency on both targets. 5) Tubulin inhibition plays a dominant role over arylsulfatase inhibition in the anti-tumor activity in this kind of dual inhibition.

Compound (**16a**) was further selected for molecular docking studies in order to explore how the CA-4 sulfamate derivatives interact with tubulin and steroid sulfatase. The protein complexes tubulin (PDB: 5LYJ)²⁴ and human placental estrone/DHEA sulfatase (PDB: 1P49)²⁵ were used for simulation in Sybyl-X 2.0. The force field was Tripos with an 8 Å cutoff for non-bonded interactions, and the atomic point charges were also calculated with the Gasteiger–Huckel method. Minimization was achieved using the steepest descent method for the first 100 steps, followed by the Broyden–Fletcher–Goldfarb–Shanno (BFGS) method until the

**Fig. 3** The binding information of CA-4 in the co-crystal structure (A, PDB code: 5LYJ) and the docking result of **16a** (B).




Fig. 4 The docking result of EMATE (A) and **16a** (B) with steroid sulfatase (PDB code: 1P49).

root-mean-square (RMS) of the gradient became <0.005 kcal/(mol Å). The Surflex-Dock module implemented in the Sybyl program was used for the docking study. The colchicine-binding site of tubulin was used and verified from the original ligand (CA-4) for docking (total score = 8.34, similarity = 0.73). The docking score and similarity of **16a** is 6.27 and 0.45, respectively. As shown in Fig. 3, the A/B ring binding mode of **16a** is almost identical to that of CA-4, both having van der Waals interaction with the same hydrophobic pocket formed by the amino acid residues VAL238, CYS241, LEU248, ALA250, LEU255, ALA316 and LYS352. The hydroxyl group of CA-4 formed a hydrogen bond with THR179, while the sulfamide group of **16a** formed two hydrogen bonds with ALA180 and ASN349.

Both EMATE and **16a** were docked into the same binding pocket of steroid sulfatase, and their docking scores were 6.16 and 5.34, respectively. As shown in Fig. 4, the hydrophobic part of EMATE and **16a** were superimposable, having van der Waals interaction with the hydrophobic pocket formed by the residues VAL101, LEU103, VAL486, HIS485, PHE488, *etc.* The sulfamate group of **16a** formed four important hydrogen bonds with the residues THR165, LYS134, ASP36 and LYS368 in the binding pocket. As for EMATE, there are six hydrogen bonds between the sulfamate group and the residues THR76, THR165, LYS134, ASP342 and ASP36. These important hydrogen bonding interactions explain why **16a** is less potent than EMATE, and the methylation of the sulfamate group (**16i** and **16j**) leads to the loss of potency for steroid sulfatase inhibition.

In summary, we have synthesized a few novel combretastatin sulfamate derivatives, and evaluated their activities on steroid sulfatase, tubulin and tumor cell proliferation inhibition. Among them, compound **16a** has a well-balanced sulfatase, tubulin and cellular inhibition potency. The SAR analysis and molecular docking study indicate that the sulfamate group is crucial for sulfatase inhibition and helpful to form additional hydrogen bonds with the colchicine-binding site of tubulin. These results highlighted that compound **16a** is a promising anticancer agent, and may be valuable in finding more effective

treatments for cancer. To the best of our knowledge, this is the first sulfamate analogue of CA-4. Further biological investigation is being conducted and the progress will be reported in the future.

Funding sources

National Natural Science Foundation of China; Innovation Program of Shanghai Municipal Education Commission; Shanghai Institute of Technology.

Abbreviations

STS	Steroid sulfatase
E1S	Estrone sulfate
DHE-AS	Dehydroepiandrosterone sulfate
DHEA	Dehydroepiandrosterone
CA-4	Combretastatin A-4
EMATE	Estrone-3-O-sulfamate
SAR	Structure-activity relationship

Author contributions

All the authors have given approval to the final version of this manuscript.

Conflicts of interest

The authors declare no competing financial interests.

Acknowledgements

Financial support from the National Natural Science Foundation of China (No. 21472126, 21302128, 21672151), the Innovation Program of Shanghai Municipal Education Commission (No. ZZZZyxx16006) and Shanghai Institute of Technology (No. YJ2016-41) is gratefully acknowledged. We are also thankful to Nanjing OGPPharmaceutical Co. Ltd., Shanghai Research Institute of Chemical Industry Co. Ltd. and Shandong Huawei Pharmaceutical Co. Ltd. for their help in bioassays.

References

- 1 J. Ahmedin, B. Freddie, M. C. Melissa, F. Jacques, W. Elizabeth and F. David, Global cancer statistics, *Ca-Cancer J. Clin.*, 2011, **61**, 69–90.
- 2 A. T. Lindsey, B. Freddie, L. S. Rebecca, F. Jacques, L. T. Joannie and J. Ahmedin, Global cancer statistics, 2012, *Ca-Cancer J. Clin.*, 2015, **65**, 87–108.
- 3 C. B. Glenn and M. E. Lee, Drug development: raise standards for preclinical cancer research, *Nature*, 2012, **483**, 531–533.
- 4 F. Jacques, S. Isabelle, D. Rajesh, E. Sultan, M. Colin, R. Marise, M. P. Donald, F. David and B. Freddie, Cancer incidence and mortality worldwide: sources, methods and major patterns in Globocan 2012, *Int. J. Cancer*, 2015, **136**, e359–e386.
- 5 S. E. S. Nagi, Y. K. Firas, E. B. Sarsh and O. A. Benjamin, Management of locally advanced and metastatic breast cancer: guidelines, infrastructures and low resource settings, *Breast Cancer Manage.*, 2016, **5**, 69–77.
- 6 R. L. Richard, Adjuvant surgical oophorectomy plus tamoxifen in premenopausal women with operable hormone receptor-positive breast cancer: A global treatment option, *Clin. Breast Cancer*, 2016, **16**, 233–237.
- 7 F. Lei, J. L. Jun, S. W. Kathrin, S. L. Jessica, F. M. Dianne, D. Y. Ke, M. S. Zhi, Q. C. Wan and E. G. Paul, Breast cancer in China, *Lancet Oncol.*, 2014, **15**, e279–e289.
- 8 (a) H. W. Lu, Y. Z. Jing, Y. Yao, Y. W. Chang, B. Z. Jian, H. S. Xiao, L. S. Xiu, X. L. Yan, X. L. Ke, Y. Hong and D. M. Xiao, Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer reagents, *Eur. J. Med. Chem.*, 2017, **142**, 493–505; (b) J. S. Lazo, Kelley E. McQueeney, James C. Burnett, Peter Wipf and E. R. Sharlow, Small molecule targeting of PTPs in cancer, *Int. J. Biochem. Cell Biol.*, 2018, **96**, 171–181; (c) A. S. A. Shah, S. S. Joshi, A. G. Ambhore, S. S. Khandelwal and R. P. Babhulkar, Short review on recent approaches of cancer therapy, *World J. Pharm. Pharm. Sci.*, 2020, **9**(8), 1431–1444.
- 9 (a) J. Allan, A. H. John, J. L. Nicholas and T. M. Alan, Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle, *Med. Res. Rev.*, 1998, **18**, 259–296; (b) K. R. Eric and C. Emiliano, Novel agents that target tubulin and related elements, *Semin. Oncol.*, 2006, **33**, 421–435; (c) Z. Cheng, X. Lu and B. Feng, A review of research progress of antitumor drugs based on tubulin targets, *Transl. Cancer Res.*, 2020, **9**(6), 4020–4027.
- 10 (a) A. Haque, M. D. A. Rahman, F. Haque, M. D. Serajul and M. S. Khan, Next Generation Antineoplastic Agents: A Review on Structurally Modified Vinblastine (VBL) Analogues, *Curr. Med. Chem.*, 2018, **25**(14), 1650–1662; (b) D. Sinha, A review on taxanes: an important group of anticancer compound obtained from *Taxus* sp, *Int. J. Pharma Sci. Res.*, 2020, **11**(5), 1969–1985; (c) M. Imran, S. Saleem, A. Chaudhuri, J. Ali and S. Baboota, Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer, *J. Drug Delivery Sci. Technol.*, 2020, **60**, 101959.
- 11 (a) Y. Lu, J. Chen, M. Xiao, W. Li and D. D. Miller, An overview of tubulin inhibitors that interact with the colchicine binding site, *Pharm. Technol.*, 2012, **29**, 2943–2971; (b) L. Y. Xia, Y. L. Zhang, R. Yang, Z. C. Wang, Y. D. Lu, B. Z. Wang and H. L. Zhu, Tubulin Inhibitors Binding to Colchicine-Site: A Review from 2015 to 2019, *Curr. Med. Chem.*, 2020, **27**(40), 6787–6814; (c) E. C. McLoughlin and N. M. O'Boyle, Colchicine-binding site inhibitors from chemistry to clinic: a review, *Pharmaceuticals*, 2020, **13**(1), 8.
- 12 S. Timo, S. Ines, K. Andreas and F. Lutz, Detection, production, and application of microbial arylsulfatases, *Appl. Microbiol. Biotechnol.*, 2016, **100**, 9053–9067.
- 13 R. L. Meng, W. Rong and S. Qing, Advances in research of arylsulfatase in tumor diagnosis and oncotherapy, *Pharm. Biotechnol.*, 2014, **21**, 81–85.
- 14 (a) S. J. Stanway, P. Delavault, A. Purohit, L. W. L. Woo, C. Thurieau, B. V. L. Potter and M. J. Reed, Steroid sulfatase: a new target for the endocrine therapy of breast cancer, *Oncologist*, 2007, **12**(4), 370–374; (b) B. V. L. Potter, Steroid Sulfatase Inhibition by Aryl Sulfamates: Clinical Progress, Mechanism and Future Prospects, *J. Mol. Endocrinol.*, 2018, **61**(2), T233–T252.
- 15 (a) L. W. L. Woo, B. Leblond, A. Purohit and B. V. L. Potter, Synthesis and evaluation of analogues of estrone-3-O-sulfamate as potent steroid sulfatase inhibitors, *Bioorg. Med. Chem.*, 2012, **20**(8), 2506–2519; (b) G. Walter, R. Liebl and E. V. Angerer, Stilbene-based inhibitors of estrone sulfatase with a dual mode of action in human breast cancer cells, *Arch. Pharm.*, 2004, **337**(12), 634–644; (c) L. W. L. Woo, C. Bubert, O. B. Sutcliffe, A. Smith, S. K. Chander, M. F. Mahon, A. Purohit, M. J. Reed and B. V. L. Potter, Dual Aromatase-Steroid Sulfatase Inhibitors, *J. Med. Chem.*, 2007, **50**(15), 3540–3560.
- 16 (a) P. T. Mark and V. L. P. Barry, Discovery and development of the aryl o-sulfamate pharmacophore for oncology and women's health, *J. Med. Chem.*, 2015, **58**, 7634–7658; (b) M. J. Reed, A. Purohit, L. W. L. Woo and B. V. L. Potter, The development of steroid sulfatase inhibitors, *Endocr.-Relat. Cancer*, 1996, **3**, 9–13; (c) S. Ramanpreet, S. Jatinder, S. Dhandeep, S. J. Amteshwar and S. Nirmal, Sulfatase inhibitors for recidivist breast cancer treatment: A chemical review, *Eur. J. Med. Chem.*, 2016, **114**, 170–190.
- 17 (a) T. Holmes, A. W. Brown, M. Suggitt, L. A. Shaw, L. Simpson, J. P. A. Harrity, G. M. Tozer and C. Kanthou, The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate, *Sci. Rep.*, 2020, **10**(1), 9926; (b) C. Deng, J. Zhao, S. Zhou, J. Dong, J. Cao, J. Gao, Y. Bai and H. Deng, The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors, *Mol. Ther.*, 2020, **28**(1), 75–88; (c) Z. M. Alghazzawy, T. K. Elmaghaby, S. A. Hagag and M. H. Awwad, Effect of vascular disrupting agent (CA-4P) and ionizing radiation on tumor growth in rats, *J. Basic Environ. Sci.*, 2019, **6**(2), 97–103.

- 18 (a) C. M. Lin, S. B. Singh, P. S. Chu, R. O. Dempcy, J. M. Schmidt, G. R. Pettit and E. Hamel, Interactions of tubulin with potent natural and synthetic analogs of the antimetabolic agent combretastatin: a structure-activity study, *Mol. Pharmacol.*, 1988, **34**, 200–208; (b) J. W. Lippert, Vascular disrupting agents, *Bioorg. Med. Chem.*, 2007, **15**, 605–615; (c) C. D. Katsetos and P. Draber, Tubulins as therapeutic targets in cancer: from bench to bedside, *Curr. Pharm. Des.*, 2012, **18**, 2778–2792; (d) M. R. Horsman, T. R. Wittenborn, P. S. Nielsen and P. B. Elming, Tumors resistant to checkpoint inhibitors can become sensitive after treatment with vascular disrupting agents, *Int. J. Mol. Sci.*, 2020, **21**(13), 4778; (e) R. Smolarczyk, J. Czaplá, M. Jarosz-Biej, K. Czerwinski and T. Cichon, Vascular disrupting agents in cancer therapy, *Eur. J. Pharmacol.*, 2021, **891**, 173692.
- 19 (a) P. L. Jing, L. C. Yi, F. K. Ming, W. C. Chun, H. Y. Tseng, C. W. Chiung, N. Y. Yung, Y. C. Jang, J. L. Shioh and P. H. Hsing, Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aryloindoles and 3-aryloindoles, as novel classes of potent antitubulin agents, *J. Med. Chem.*, 2004, **47**, 4247–4257; (b) C. M. Lin, H. H. Ho, G. R. Pettit and E. Hamel, Antimetabolic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin, *Biochemistry*, 1989, **28**, 6984–6991; (c) A. Siebert, M. Gensicka, G. Cholewinski and K. Dzierzbicka, Synthesis of combretastatin A-4 analogs and their biological activities, *Anti-Cancer Agents Med. Chem.*, 2016, **16**, 942–960; (d) A. Z. Nikolay and O. N. Zefirova, Heterocycles as classical and nonclassical ring B isosters in combretastatin A-4, *Chem. Heterocycl. Compd.*, 2017, **53**, 273–280; (e) S. Arora, A. F. Gonzalez and K. Solanki, Combretastatin A-4 and its analogs in cancer therapy, *Int. J. Pharm. Sci. Rev. Res.*, 2013, **22**, 168–174; (f) D. Tarade, D. Ma, C. Pignatelli, F. Mansour, D. Simard, S. V. D. Berg, J. Gauld, J. McNulty and S. Pandey, Structurally simplified biphenyl combretastatin A4 derivatives retain in vitro anti-cancer activity dependent on mitotic arrest, *PLoS One*, 2017, **12**(3), e0171806; (g) C. Jie, Y. Jun, H. H. Jin, Q. P. Yan, H. Lin and S. L. Xing, Synthesis, biological evaluation and mechanism study of chalcone analogues as novel anti-cancer agents, *RSC Adv.*, 2015, **5**, 68128–68135.
- 20 (a) C. Sessa, P. Lorusso, A. Tolcher, F. Farace, N. Lassau, A. Delmonte, A. Braghetta, R. Bahleda, P. Cohen and M. Hospitel, *et al.* Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors, *Clin. Cancer Res.*, 2013, **19**(17), 4832–4842; (b) F. A. L. M. Eskens, P. Tresca, D. Tosi, L. Van Doorn, H. Fontaine, A. Van der Gaast, C. Veyrat-Follet, C. Oprea, M. Hospitel and V. Dieras, A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours, *Br. J. Cancer*, 2014, **110**(9), 2170–2177; (c) R. Bahleda, C. Sessa, G. D. Conte, L. Gianni, G. Capri, A. Varga, C. Oprea, B. Daghli, M. Hospitel and J. C. Soria, Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors, *Invest. New Drugs*, 2014, **32**(6), 1188–1196; (d) E. B. Garon, J. D. Neidhart, N. Y. Gabrail, M. R. D. Oliveira, J. Balkissoon and F. Kabbavar, A randomized Phase II trial of the tumor vascular disrupting agent CA 4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer, *OncoTargets Ther.*, 2016, **9**, 7275–7283; (e) B. J. Monk, M. W. Sill, J. L. Walker, C. J. Darius, G. Sutton, K. S. Tewari, L. P. Martin, J. M. Schilder, R. L. Coleman and J. Balkissoon, *et al.* Randomized phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: an NRG oncology/gynecologic oncology group study, *J. Clin. Oncol.*, 2016, **34**(19), 2279–2286.
- 21 (a) Z. L. Ma, X. J. Yan, L. Zhao, J. J. Zhou, W. Pang, Z. P. Kai and F. H. Wu, Combretastatin A-4 and their derivatives: potential fungicides targeting fungal tubulin, *J. Agric. Food Chem.*, 2016, **64**, 746–751; (b) L. Zhao, J. J. Zhou, X. Y. Huang, L. P. Cheng, W. Pang, Z. P. Kai and F. H. Wu, Design, synthesis and antiproliferative effects in tumor cells of new combretastatin A-4 analogs, *Chin. Chem. Lett.*, 2015, **26**, 993–999; (c) S. W. Zhang, T. Li, W. Pang, J. J. Wu, F. L. Wu, Y. Y. Liu and F. H. Wu, Synthesis, biological evaluation and molecular docking studies of Combretastatin A-4 phosphoramidates as novel anticancer prodrugs, *Med. Chem. Res.*, 2020, **29**(12), 2192–2202.
- 22 K. Kamath, O. Tatiana, L. Gary, P. Dulal, W. Leslie and A. J. Mary, 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules, *Mol. Cancer Ther.*, 2006, **5**(9), 2225–2233.
- 23 (a) M. D. Lloyd, N. Thiyagarajan, Y. T. Ho, L. W. L. Woo, O. B. Sutcliffe, A. Purohit, M. J. Reed, K. R. Acharya and B. V. L. Potter, First Crystal Structures of Human Carbonic Anhydrase II in Complex with Dual Aromatase-Steroid Sulfatase Inhibitors, *Biochemistry*, 2005, **44**, 6858–6866; (b) L. W. L. Woo, T. Jackson, A. Putey, G. Cozier, P. Leonard, K. R. Acharya, S. K. Chander, A. Purohit, M. J. Reed and B. V. L. Potter, Highly Potent First Examples of Dual Aromatase-Steroid Sulfatase Inhibitors based on a Biphenyl Template, *J. Med. Chem.*, 2010, **53**, 2155.
- 24 G. Roberto, E. P. Andrea, B. Katja, C. Andrea and O. S. Michel, Structural basis of cis- and trans-combretastatin binding to tubulin, *Chem*, 2017, **2**, 102.
- 25 G. Debashis, Three-dimensional structures of sulfatases, *Methods Enzymol.*, 2005, **400**, 273–293.